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In this study, full-genome DNA microarrays based on the sequence of Staphylococcus aureus N315 were used
to compare the transcriptome of a clinical S. aureus strain with a normal phenotype to that of its isogenic
mutant with a stable small-colony-variant (SCV) phenotype (hemB::ermB). In addition to standard statistical
analyses, systems biology advances were applied to identify reporter metabolites and to achieve a more detailed
survey of genome-wide expression differences between the hemB mutant and its parental strain. Genes of
enzymes involved in glycolytic and fermentative pathways were found to be up-regulated in the hemB mutant.
Furthermore, our analyses allowed identiﬁcation of additional differences between the normal-phenotype S.
aureus and the SCV, most of which were related to metabolism. Profound differences were identiﬁed especially
in purine biosynthesis as well as in arginine and proline metabolism. Of particular interest, a hypothetical gene
of the Crp/Fnr family (SA2424) that is part of the arginine-deiminase (AD) pathway, whose homologue in
Streptococcus suis is assumed to be involved in intracellular persistence, showed signiﬁcantly increased tran-
scription in the hemB mutant. The hemB mutant potentially uses the up-regulated AD pathway to produce ATP
or (through ammonia production) to counteract the acidic environment that prevails intracellularly. Moreover,
genes involved in capsular polysaccharide and cell wall synthesis were found to be signiﬁcantly up-regulated
in the hemB mutant and therefore potentially responsible for the changed cell morphology of SCVs. In
conclusion, the identiﬁed differences may be responsible for the SCV phenotype and its association with
chronic and persistent infections.
The opportunistic pathogen Staphylococcus aureus is one of
the major causes of nosocomial and community-acquired dis-
eases that may range from superﬁcial skin infections to life-
threatening systemic infections and toxicoses (15). The ability
of this species to cause such a wide spectrum of disease and to
adapt to changing conditions is conferred by an impressive
arsenal of pathogenicity and virulence factors that are globally
regulated (3).
S. aureus may have an intrinsic ability for resisting treatment
with antimicrobial agents that extends beyond what are now
considered classical mechanisms of drug resistance (24). The
discovery and characterization of a naturally occurring sub-
population of S. aureus, designated small-colony variants
(SCVs), and their association with chronic and persistent in-
fections have provided new insight into the understanding of
the pathogenesis of S. aureus (26). Several studies showed that
SCVs, in contrast to their normal-phenotype parental strain
progenitors, can be internalized by and persist within nonpro-
fessional phagocytes (34–36). The capacity of SCVs to persist
intracellularly and to hide within host cells can be regarded as
a strategy of the bacteria for survival within the host and an
additional strategy to evade antibiotic challenge and host de-
fenses (26).
Clinical (i.e., genetically undeﬁned) SCVs are frequently
auxotrophic for hemin or menadione, two compounds involved
in the synthesis of the electron carriers cytochrome and mena-
quinone, respectively, and exhibit a high rate of reversion to a
normal, large-colony form. The genetic nature of the observed
auxotrophies and the instability of the auxotrophic phenotype
remain to be determined. To create a genetically and pheno-
typically stable SCV, a hemB-knockout mutant was created
by allelic exchange (36). Genetically deﬁned S. aureus hemB
mutants have been compared with SCVs recovered from
clinical specimens and have proved to exhibit the major
characteristics of the SCV phenotype of clinical strains: slow
growth, decreased pigment formation, resistance to amino-
glycosides, low coagulase activity, and reduced hemolytic
activity (1, 29, 30, 34, 36).
To provide a more complete analysis of SCV phenotypes
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7765and to gain a clearer insight into physiological changes that
lead to in vivo antibiotic resistance and persistence, SCV mu-
tants that reproduce the SCV phenotype were compared to
their parental strain by various approaches. By application of a
high-resolution two-dimensional protein gel electrophoresis
technique coupled with matrix-assisted laser desorption ion-
ization–time of ﬂight mass spectrometry, proteins involved in
the glycolytic pathway and in fermentation pathways were
found to be induced in an exponentially growing hemB mutant
compared to its wild-type parental strain (12). Again compared
to the parent strain, phenotype microarray analysis of over
1,500 phenotypes revealed that a hemB mutant was defective in
utilizing a variety of carbon sources including tricarboxylic acid
(TCA) cycle intermediates and compounds that generate ATP
via electron transport (37). Furthermore, hexose phosphates
and other carbohydrates that provide ATP in the absence of
electron transport stimulated growth of the hemB mutant com-
pared to its wild-type parental precursor strain. Finally, based
on a subgenomic DNA microarray analysis (i.e., 460 genes), it
has been suggested that SigB might play a role in the expres-
sion of the SCV phenotype (19).
Despite these recent analyses of SCV phenotype and in-
sights into the physiological differences between the normal
phenotype and the SCV, we are still lacking an understanding
of the signaling and regulatory mechanisms underlying the
expression of the SCV phenotype of S. aureus. It is anticipated
that identiﬁcation of differences between the normal pheno-
type and SCV phenotype might provide clues into this cir-
cuitry. Here, genome-wide techniques offer unprecedented
potential for identiﬁcation of undiscovered phenotypic differ-
ences as these techniques screen on a system-wide level. In
none of the previous studies was a complete analysis of genes
differentially expressed in SCV and normal-phenotype S. au-
reus performed.
In this study, a comparative, genome-wide transcriptome
analysis of an S. aureus hemB mutant displaying the clinical
SCV phenotype versus the wild-type parental strain with nor-
mal phenotype was conducted. First, we employed a standard
statistical analysis of the transcription data. Second, we har-
nessed the potential of recent systems biology advances to
analyze the simple but notoriously overwhelming transcrip-
tome data. We employed a recent genome-scale reconstruction
of the S. aureus metabolic network (7) and a novel pathway-
driven computational algorithm (20) to further extract metab-
olism-related transcriptional differences between the mutant
and the parental strain.
MATERIALS AND METHODS
Bacterial strains and growth conditions. S. aureus wild-type strain A22223I,
recovered from a ﬁstula tract of a patient with chronic osteomyelitis and most
recently used in a Caenorhabditis elegans infection model (30), and its isogenic
hemB mutant (A22223I hemB::ermB), displaying the small-colony-variant phe-
notype, were used for all experiments. The strain A22223I was selected as the
parent strain for the construction of the hemB mutant, because the strain was
recovered in parallel with an S. aureus isolate displaying the SCV phenotype. As
this hemin-auxotrophic SCV isolate revealed an unstable phenotype, exhibiting
a high rate of reversion to the large-colony form, the isogenic parent strain
A22223I was used to construct a genetically deﬁned and stable SCV phenotype.
This hemB mutant was constructed by allelic replacement with an ermB cassette-
inactivated hemB gene, as previously described (34, 36). Furthermore, a com-
plemented mutant with restored normal phenotype was constructed as previously
reported (36). To keep the strains in a low passage number, strains were taken
from stored small aliquots. Overnight cultures in tryptic soy broth (TSB) medium
(Becton Dickinson GmbH, Heidelberg, Germany) were inoculated with a single
colony. In precultures (prior to RNA isolation), the hemB mutant was grown in
TSB supplemented with erythromycin at a concentration of 2.5 g/ml.
RNA isolation. For RNA isolation, shaking ﬂasks (100 ml TSB in 500-ml ﬂasks
as used in a previous study [12]) were inoculated to an optical density at 578 nm
of 0.05 into fresh TSB medium at 37°C and 160 rpm by using overnight cultures
(15). Samples were collected and processed at least in triplicate to analyze at
least three RNA samples for each strain and time point. Cells of the parent strain
were harvested after 150, 270, 375, 480, and 600 min and cells of the hemB
mutant after 240, 330, 390, 495, and 600 min, to provide bacteria in the same
growth phase (Fig. 1) and as performed in a previous study (12). A volume of 10
ml of a bacterial suspension of the parent strain was immediately mixed with 10
ml of RNAprotect (QIAGEN, Hilden, Germany), vortexed for 5 s, incubated for
5 min at room temperature, and pelleted by centrifugation for 10 min at 4,000 
g. To compensate for the difference in cell number, 10 10-ml-volume suspensions
of the hemB mutant were pelleted by centrifugation (10 min at 4,000  g). Each
pellet was immediately resuspended in 1 ml of RNAprotect (QIAGEN). Then,
the 10 hemB mutant suspensions were pooled, vortexed for 5 s, incubated for 5
min at room temperature, and harvested by centrifugation (10 min at 4,000  g).
The pooled bacterial pellets were resuspended in 1 ml RNApro solution (Qbio-
gene, Heidelberg, Germany) and puriﬁed on a Matrix E column (Qbiogene).
Cells were separated by mechanical lysis using a FastPrep Instrument (Qbio-
gene): once at 30 s, attitude of disruption 6.5, 30 s on ice, and once at 30 s,
attitude 6.5. Further RNA puriﬁcation was performed using the RNeasy Mini Kit
(QIAGEN) according to the manufacturer’s recommendations. Contaminating
DNA in the RNA preparations was removed using DNase as described by the
manufacturer (QIAGEN).
The RNA quality and quantity were determined by measurement of the
absorbance at 260 and 280 nm (Eppendorf BioPhotometer; Hamburg, Germany)
and agarose gel electrophoresis (intact rRNA bands). Puriﬁed RNA was stored
at 70°C. Independent samples of RNA were used for each time point on
separate microarrays.
cDNA synthesis, labeling, and microarray hybridization. S. aureus N315 mi-
croarrays were purchased from Scienion (Scienion AG, Berlin, Germany) and
were produced by spotting 2,338 PCR products (of the 2,593 open reading
frames [ORFs] of the annotated genome of S. aureus N315 [reference identiﬁ-
cation: NC_002745]) on a glass slide (details about the microarrays can be found
at http://www.scienion.com). Each open reading frame was present in duplicate
on the microarray. cDNA was synthesized from mRNA as recommended by the
manufacturer of the microarray: RNA (12 g unless otherwise indicated) from
either A22223I or its hemB mutant was mixed with 1 g of random hexamer
primer (Invitrogen, Karlsruhe, Germany), 1 l of RNase OUT (Invitrogen), and
RNase-free water up to a volume of 10 l. The samples were denatured at 70°C
for 10 min and then cooled on ice for 1 min. Labeled cDNA was synthesized by
mixing the denatured RNA with 200 U of Superscript III reverse transcriptase
(Invitrogen), Cy3- and Cy5-dUTP, deoxynucleoside triphosphate mix, and ap-
propriate buffer in a reaction mix according to the manufacturer’s protocol
(Scienion). The mixture was incubated for 10 min at 25°C, followed by incubation
at 47°C for 60 min. Two hundred units of Superscript III reverse transcriptase
(Invitrogen) was added again, followed by a further incubation for 40 min at
47°C. The reaction was stopped by adding 5 l of 500 mM EDTA. Then, the
mixture was incubated for 15 min at 65°C after NaOH (5 l, 1 M) was added to
hydrolyze the RNA. The sample was neutralized with 12.5 l of Tris-HCl (1 M,
pH 7.5), and the resulting cDNA was puriﬁed using a QIAquick PCR puriﬁcation
kit (QIAGEN). The volumes of the labeled cDNA solutions were reduced to 3
l by using a SpeedVac (Thermo Electron Corp., Waltham, MA). The Cy3- and
Cy5-labeled cDNA solutions were mixed, resuspended in 49 l of prewarmed
(48°C) hybridization solution (Scienion), and incubated for 5 min at 48°C. The
mixture of labeled products was denatured for 2 min at 95°C. The combined
samples were hybridized to the S. aureus N315 microarrays for 72 h at 48°C. The
slides were washed according to the manufacturer’s protocol and stored at
70°C. For each of the ﬁve time points, at least three DNA microarrays plus one
dye-switch experiment (to check cDNA synthesis and labeling) were analyzed.
Data analysis. The hybridized microarrays were scanned with a GMS418 array
scanner (Affymetrix, Santa Clara, CA). A geometric raster was laid over the
resulting microarray picture to distinguish the signals from the background. After
localization of single spots, the spot intensities and the global background were
calculated.
The hybridization patterns and intensities were quantitatively analyzed using
the Imagene 6 software (BioDiscovery, El Segundo, CA). The replicates were
averaged, and the spots identiﬁed by Imagene 6 as ﬂawed were omitted. The data
set was normalized by application of the LOWESS algorithm. The data from
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Excel (Microsoft Corporation, Redmond, WA) software for further analysis as,
e.g., identiﬁcation of microarrays that present technical outliers. The expression
intensities of one single array, resulting from multiple scans with different gains,
were averaged. In a next step, the averaged intensity values of all arrays for each
time point as well as for all time points combined were used for t tests. Genes
with a change of 0.4- or 2.0-fold were characterized as having signiﬁcantly
differing amounts of transcripts based on t tests with a P value cutoff of at least
0.05. Gene functions were assigned to the respective accession numbers and
annotations as compiled on DOGAN, a web page for S. aureus N315 (http://www
.bio.nite.go.jp/dogan/MicroTop?GENOME_IDn315G1). Fisher’s exact test
was used to decide whether functional annotations show a tendency of over- or
underrepresentation in a candidate gene list compared to all measured and
annotated items.
The microarray data were also analyzed by a recently developed algorithm that
uses the topology of an organism’s metabolic network to uncover underlying
metabolism-related transcriptional regulation (20). This algorithm ﬁrst converts
a genome-scale metabolic network (we employed the recently reconstructed
genome-scale metabolic network of S. aureus N315 [7]) into a bipartite metabolic
graph. In this graph, each metabolite node is then scored based on the normal-
ized transcriptional response of its neighboring enzymes. Using the genes’ P
values as inputs to score the enzyme nodes, the algorithm identiﬁes so-called
reporter metabolites, designating metabolites around which the most signiﬁcant
transcriptional changes occur. The mapping of transcription data onto a meta-
bolic network, which underlies the employed algorithm, allows identifying spots
(so-called reporter metabolites) around which signiﬁcant regulation occurs and
thus assists in carving out metabolism-related insight from the microarray data.
Validation of array data by real-time PCR. To determine the validity of the
array data, selected transcriptional changes obtained with the microarray analysis
were compared with those from quantitative real-time PCR. For a list of the
genes and primer sequences used for the real-time PCR analysis, see Table S1 in
the supplemental material. The real-time PCR was performed by using the
iCycler (Bio-Rad Laboratories GmbH, Munich, Germany) with a QuantiTect
reverse transcription kit (QIAGEN) and the DyNAmo HS SYBR Green qPCR
Kit (Finnzymes Oy, Espoo, Finland). Reaction mixtures were initially incubated
for 15 min at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 55.0°C, and 30 s
at 72°C. PCR efﬁciencies were derived from standard curve slopes in the iCycler
software v. 3.0a (Bio-Rad Laboratories). The expression rates were calculated
using Gene Expression Analysis for iCycler iQ Real-Time PCR Detection Sys-
tem v1.10 (Bio-Rad Laboratories). Melting-curve analysis was also performed to
evaluate PCR speciﬁcity and resulted in single, primer-speciﬁc melting temper-
atures.
RESULTS AND DISCUSSION
SCVs recovered from clinical specimens are frequently
auxotrophic for hemin. For S. aureus, in vitro gentamicin-
selected SCVs are found that carry mutations in the hem
operon, which encodes enzymes required for hemin biosynthe-
sis (28). Furthermore, an Escherichia coli SCV has been iso-
lated from a patient and has been shown to carry a hemB
mutation that renders the bacterium defective in hemin bio-
FIG. 1. Growth of the S. aureus A22223I parental wild-type strain (}) and its isogenic hemB mutant (■ ) in TSB (with standard deviations). The
times of sampling for transcriptional analysis are indicated by the symbols on the growth curves. Time points for RNA isolation were selected as
previously described (12). Optical density was measured at 578 nm.
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aureus SCV hemB mutant was employed to serve as a model
organism for the transcriptional changes that occur upon loss
of hemin biosynthesis. The model organism was used to limit
the uncertainty associated with using an undeﬁned genetic
background and reversible phenotypes found in genetically
undeﬁned clinical SCVs and gentamicin-induced SCVs (36).
Past studies using deﬁned S. aureus hemB mutants, in part in
comparison with clinical SCVs, had previously shown that this
organism confers the major features of the SCV phenotype (1,
9, 12, 29, 30, 34, 36, 37).
Transcriptional differences between the S. aureus hemB mu-
tant and its parent strain. In this study, the hemB mutant
displaying the SCV phenotype was applied on a full-genome
microarray to get a complete view of the transcriptional proﬁle
of SCVs. More speciﬁcally, we compared the expression levels
of the S. aureus hemB mutant and its parent strain at ﬁve time
points, corresponding to different growth phases: lag phase,
early exponential phase, mid-exponential phase, late exponen-
tial phase, and stationary phase (Fig. 1).
To verify the microarray data, quantitative real-time reverse
transcription-PCR studies were performed for selected genes
of the S. aureus parent strain, its hemB mutant, and its com-
plemented mutant. In fact, the results of quantitative real-time
reverse transcription-PCR analyses of selected transcripts were
found to be in excellent accordance with the microarray anal-
ysis. This was true for the pooled time points (Table 1) as well
as for the single time points (data not shown).
With the standard statistical analysis of the acquired ge-
nome-wide transcription data, when values from different
growth phases were pooled, 170 genes were found to be sig-
niﬁcantly changed when the wild-type and the hemB-disrupted
strains were compared. Compared to the parent strain, 48 of
these genes were signiﬁcantly down-regulated and 122 genes
were signiﬁcantly up-regulated in the hemB mutant. All signif-
icantly differently expressed genes in the combined analysis of
all values from all growth phases are listed in Table 2. Data
from each phase of growth are listed in Tables S2 to S6 in the
supplemental material. To reveal functional groups of genes
that are in general differentially expressed in the hemB mutant
compared to the parent strain, we performed Fisher’s exact
test using the classiﬁcation from the DOGAN web page (re-
sults are shown in Table 3).
As demonstrated in past studies, the phenotype of the hemB
mutant is characterized by a signiﬁcantly reduced growth rate
and an excretion of lactate instead of acetate, both giving
indication of metabolic differences between the mutant and its
parental strain. In fact, recent proteomic and phenotypic mi-
croarray studies underlined the signiﬁcance of metabolic dif-
ferences, such as the defect of the hemB mutant in utilization
of a variety of carbon sources, including TCA cycle interme-
diates and compounds that ultimately generate ATP via elec-
tron transport. Furthermore, hexose phosphates and other
carbohydrates that provide ATP in the absence of electron
transport were found to stimulate growth of the hemB mu-
tant (12, 37). Thus, besides the standard statistical analysis
we put a special focus on metabolism-related transcriptional
changes by using a recently developed algorithm from sys-
tems biology (20).
Before using this algorithm, we ﬁrst extracted the genes
from the microarray data that are related to metabolic func-
tions. For this, we employed the recently reconstructed S. au-
reus metabolic network (7), leaving us with approximately 560
genes that encode enzymes where substrates and products are
known. In a next step, we used the computational method of
Patil and Nielsen (20) to computationally map the transcrip-
tional changes of this set of genes onto the metabolic network
(cf. Materials and Methods). Thus, by this linking of transcrip-
tion data with metabolism (in contrast to an otherwise isolated
analysis of single genes) the transcriptional changes in the
hemB mutant (compared to its wild-type strain) were consid-
ered in a metabolic context. In fact, this approach enables a
condensation of transcriptional data to a number of metabo-
lites around which substantial transcriptional changes occur.
Patil and Nielsen called these metabolites “reporter metabo-
lites” (20) as they mark spots in the metabolism around which
regulation occurs most likely in order to either increase, de-
crease, or redirect a metabolic ﬂux. In a broader view, com-
TABLE 1. Validation of array data by real-time PCR
a
Gene identiﬁer Gene
Quantitative real-time RT-PCR
b result
(relative difference in expression change)
Expression difference of the
hemB mutant analyses
compared to the wild type
using microarrays
c hemB
mutant
Complemented
mutant Wild type
SA0150 Capsular polysaccharide synthesis enzyme Cap5G 29.9 1.1 1.0 Sig. up-reg.
SA0232 L-Lactate dehydrogenase 21.1 1.0 1.2 Sig. up-reg.
SA0742 Fibrinogen-binding protein A 494.6 12.6 1.0 Sig. up-reg.
SA0922 Phosphoribosylpyrophosphate amidotransferase PurF 1.0 24.3 10.6 Sig. down-reg.
SA1141 Glycerol kinase 40.8 3.6 1.0 Sig. up-reg.
SA1142 Aerobic glycerol-3-phosphate dehydrogenase 128.0 1.0 2.4 Sig. up-reg.
SA2206 Immunoglobulin G-binding protein SBI 1.0 4.3 8.3 Sig. down-reg.
SA2424 Hypothetical protein, similar to transcription
regulator Crp/Fnr family protein
163.1 1.0 1.3 Sig. up-reg.
SA2426 Arginine/ornithine antiporter 891.0 1.0 1.3 Sig. up-reg.
SA2428 Arginine deiminase 989.0 2.1 1.0 Sig. up-reg.
a Transcription rates of selected genes for the S. aureus hemB mutant in comparison to the wild type and the complemented mutant for pooled time points.
The relative differences in expression change were calculated using Gene Expression Analysis for iCycler iQ Real-Time PCR Detection System v1.10 (Bio-Rad).
The lowest expression was set to 1.0. gyrA (SA0006) was used as a housekeeping gene for relative quantiﬁcation.
b RT-PCR, reverse transcription-PCR.
c See Table 2. Abbreviations: sig. up-reg., signiﬁcantly up-regulated; sig down-reg., signiﬁcantly down-regulated.
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Function group and ORF (N315) P value
by t test
a
Fold
change
b Description
Adaptation to atypical conditions
SA0147 0.00 3.16 Capsular polysaccharide synthesis Cap5D
SA0144 0.00 3.60 Capsular polysaccharide synthesis Cap5A
SA1549 0.00 2.64 Hypothetical protein similar to serine proteinase Do heat shock protein HtrA
SA0145 0.00 2.65 Capsular polysaccharide synthesis Cap5B
SA2494 0.00 3.05 Cold shock protein
SA1096 0.00 2.23 Heat shock protein
SA0146 0.00 2.89 Capsular polysaccharide synthesis Cap8C
SA2336 0.00 2.30 ATP-dependent Clp proteinase chain ClpL
SA0148 0.01 2.60 Capsular polysaccharide synthesis Cap8E
SA0150 0.03 2.04 Capsular polysaccharide synthesis Cap5G
SA0149 0.03 2.14 Capsular polysaccharide synthesis Cap5F
Antibiotic production
SA0173 0.01 2.19 Hypothetical protein similar to surfactin synthetase
Cell wall
SA1691 0.00 3.52 Hypothetical protein similar to protein 1A/1B
SA1283 0.00 2.14 Penicillin-binding protein 2
SA1024 0.00 2.32 Penicillin-binding protein 1
Membrane bioenergetics
(electron transport chain
and ATP synthase)
SA0411 0.00 5.00 NADH dehydrogenase subunit
SA0211 0.00 0.10 Hypothetical protein similar to NADH-dependent dehydrogenase
SA0210 0.00 0.13 Hypothetical protein similar to NADH-dependent dehydrogenase
SA0366 0.00 0.38 Alkyl hydroperoxide reductase C
SA0938 0.01 2.13 Cytochrome d ubiquinol oxidase subunit II homologue
SA1132 0.02 2.34 Hypothetical protein similar to ferredoxin oxidoreductase beta subunit
SA0937 0.02 2.14 Cytochrome d ubiquinol oxidase subunit I homologue
SA1311 0.02 2.12 Hypothetical protein similar to thioredoxin reductase homologue
SA1315 0.03 2.31 Ferredoxin
Metabolism of amino acids and
related molecules
SA2428 0.00 4.96 Arginine deiminase
SA2341 0.00 0.38 1-Pyrroline-5-carboxylate dehydrogenase
SA1165 0.00 0.39 Threonine synthase
SA1166 0.00 0.39 Homoserine kinase homologue
SA0419 0.01 2.13 Cystathionine gamma-synthase
SA0416 0.01 2.05 Hypothetical protein similar to carboxylesterase
SA2427 0.02 4.24 Ornithine transcarbamoylase
SA2389 0.03 2.06 Truncated hypothetical protein similar to metalloproteinase Mpr precursor
Metabolism of carbohydrates and
related molecules
SA1142 0.00 5.46 Aerobic glycerol-3-phosphate dehydrogenase
SA0945 0.00 0.35 Dihydrolipoamide S-acetyltransferase component of pyruvate
dehydrogenase complex E2
SA1245 0.00 0.20 2-Oxoglutarate dehydrogenase E1
SA2008 0.00 3.40 Alpha-acetolactate synthase
SA0730 0.00 2.38 Phosphoglycerate mutase
SA1184 0.00 0.34 Aconitate hydratase
SA1244 0.00 0.26 Dihydrolipoamide succinyltransferase
SA1141 0.00 2.57 Glycerol kinase
SA0728 0.00 2.43 Phosphoglycerate kinase
SA2007 0.00 2.68 Hypothetical protein similar to alpha-acetolactate decarboxylase
SA0729 0.00 2.16 Triosephosphate isomerase
SA0182 0.00 0.36 Hypothetical protein similar to indole-3-pyruvate decarboxylase
SA1553 0.00 0.33 Formyltetrahydrofolate synthetase
SA1089 0.00 0.38 SucD succinyl coenzyme A synthetase alpha chain
SA2327 0.00 2.27 Hypothetical protein similar to pyruvate oxidase
SA1554 0.00 0.30 Acetyl coenzyme A synthetase
SA0232 0.00 40.16 L-Lactate dehydrogenase
SA0219 0.01 2.22 Formate acetyltransferase activating enzyme
Continued on following page
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Function group and ORF (N315) P value
by t test
a
Fold
change
b Description
SA0654 0.02 2.40 Fructose 1-phosphate kinase
SA1517 0.02 0.39 Isocitrate dehydrogenase
Metabolism of coenzymes and
prosthetic groups
SA1492 0.00 2.06 Delta-aminolevulinic acid dehydratase
Metabolism of nucleotides and
nucleic acids
SA0923 0.00 0.22 Phosphoribosylformylglycinamidine cycloligase PurM
SA0924 0.00 0.23 Phosphoribosylglycinamide formyltransferase
SA0921 0.00 0.24 Phosphoribosylformylglycinamidine synthetase PurL
SA0922 0.00 0.26 Phosphoribosylpyrophosphate amidotransferase PurF
SA0916 0.00 0.28 Hypothetical protein similar to phosphoribosylaminoimidazole carboxylase PurE
SA0925 0.00 0.27 Bifunctional purine biosynthesis PurH
SA0920 0.00 0.34 Phosphoribosylformylglycinamidine synthase II
SA2297 0.00 2.63 Hypothetical protein similar to GTP-pyrophosphokinase
SA0373 0.00 0.32 Xanthine phosphoribosyltransferase
SA0918 0.01 0.39 Phosphoribosylaminoimidazolesuccinocarboxamide synthetase homologue
Metabolism of phosphate
SA2301 0.00 2.27 Hypothetical protein similar to alkaline phosphatase
No similarity
SA2221 0.00 3.60 Hypothetical protein
SA1476 0.00 5.66 Hypothetical protein
SA2011 0.00 4.10 Hypothetical protein
SA2272 0.00 2.05 Hypothetical protein
SA1774 0.00 2.29 (Bacteriophage phiN315) hypothetical protein
SA0536 0.00 3.20 Hypothetical protein
SA2091 0.00 0.26 Hypothetical protein
SA1773 0.00 2.26 (Bacteriophage phiN315) hypothetical protein
SA1772 0.00 2.48 (Bacteriophage phiN315) hypothetical protein
SA1703 0.00 3.22 Hypothetical protein
SA0535 0.01 2.47 Hypothetical protein
SA0885 0.02 2.12 Hypothetical protein
SA2113 0.03 2.25 Hypothetical protein
SAS014 0.03 2.22 Hypothetical protein
SA2268 0.04 2.16 Hypothetical protein
Pathogenic factors (toxins and
colonization factors)
SA0587 0.00 0.13 Lipoprotein streptococcal adhesin PsaA
SA2430 0.00 2.37 Zinc metalloproteinase aureolysin
SA2206 0.00 0.29 Immunoglobulin G-binding protein SBI
SA0390 0.00 3.81 (Pathogenicity island SaPIn2) 14
SA2097 0.01 2.68 Hypothetical protein similar to secretory antigen precursor SsaA
SA0742 0.01 2.14 Fibrinogen-binding protein A
SA2356 0.02 2.12 Immunodominant antigen A
Phage-related functions
SA1796 0.00 6.74 (Bacteriophage phiN315) hypothetical protein
SA1782 0.00 2.86 (Bacteriophage phiN315) hypothetical protein
SA1785 0.00 2.04 (Bacteriophage phiN315) hypothetical protein
SA1783 0.01 2.38 (Bacteriophage phiN315) hypothetical protein
SA1788 0.02 2.03 (Bacteriophage phiN315) hypothetical protein
SA1775 0.02 2.31 (Bacteriophage phiN315) hypothetical protein
SA1797 0.02 2.12 (Bacteriophage phiN315) hypothetical protein
Protein folding
SA1659 0.00 2.89 Peptidyl-prolyl cis/trans isomerase homologue
RNA modiﬁcation
SA1713 0.02 2.10 RNA methyltransferase homologue
SA1885 0.02 2.13 Hypothetical protein similar to RNA helicase
RNA synthesis
SA2424 0.00 9.18 Hypothetical protein similar to transcription regulator Crp/Fnr family protein
Continued on facing page
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Function group and ORF (N315) P value
by t test
a
Fold
change
b Description
SA2092 0.00 0.20 Hypothetical protein similar to transcription regulator
SA1949 0.00 4.15 Lytic regulatory protein truncated with Tn554
SA1956 0.00 3.35 Lytic regulatory protein truncated with Tn554
SA1700 0.00 4.09 Two-component response regulator
SA2429 0.00 3.61 Hypothetical protein similar to arginine repressor
SA0108 0.00 0.30 Staphylococcal accessory regulator A
SA2296 0.00 2.71 Hypothetical protein similar to transcriptional regulator MerR family
SA2103 0.00 2.20 Hypothetical protein similar to divergon expression attenuator LytR
SA1139 0.00 2.11 Glycerol uptake operon regulatory protein
SA0653 0.00 2.82 Hypothetical protein similar to repressor of fructose operon
SA1961 0.00 2.26 Hypothetical protein similar to transcription antiterminator BglG family
SA2418 0.01 2.18 Hypothetical protein similar to response regulator
SA0187 0.01 0.39 Hypothetical protein similar to transcription regulator
SA2295 0.03 2.65 Gluconate operon transcriptional repressor
SA2287 0.03 2.06 Staphylococcal accessory regulator A
Sensors (signal transduction)
SA1701 0.00 4.09 Two-component sensor histidine kinase
SA1653 0.00 2.03 Signal transduction protein
SA2417 0.01 2.15 Hypothetical protein similar to sensor histidine kinase
Similar to unknown proteins
SA0175 0.00 5.39 Conserved hypothetical protein
SA1702 0.00 3.31 Conserved hypothetical protein
SA0412 0.00 5.20 Conserved hypothetical protein
SA0213 0.00 0.23 Conserved hypothetical protein
SA2220 0.00 3.26 Conserved hypothetical protein
SA0413 0.00 2.83 Conserved hypothetical protein
SA0212 0.00 0.14 Conserved hypothetical protein
SA0588 0.00 0.13 Conserved hypothetical protein
SA2329 0.00 3.96 Conserved hypothetical protein
SA1712 0.00 3.19 Conserved hypothetical protein
SA0908 0.00 3.66 Conserved hypothetical protein
SA2146 0.00 2.72 TcaA protein
SA0919 0.00 0.31 Conserved hypothetical protein
SA0725 0.00 2.75 Conserved hypothetical protein
SA1021 0.00 2.33 Conserved hypothetical protein
SA1031 0.00 2.67 Conserved hypothetical protein
SA1032 0.00 2.17 Conserved hypothetical protein
SA0824 0.00 2.29 Conserved hypothetical protein
SA1433 0.01 0.37 Conserved hypothetical protein
SA0301 0.01 0.40 Conserved hypothetical protein
SA0962 0.01 2.08 Conserved hypothetical protein
SA1033 0.02 2.38 Conserved hypothetical protein
SA2481 0.02 2.23 Conserved hypothetical protein
SA0415 0.02 2.16 Conserved hypothetical protein
SA2298 0.03 2.01 Conserved hypothetical protein
SA0174 0.04 2.01 Conserved hypothetical protein
SA1071 0.04 2.02 Conserved hypothetical protein
Transport/binding proteins and
lipoproteins
SA2426 0.00 16.29 Arginine/ornithine antiporter
SA0541 0.00 4.96 Hypothetical protein similar to amino acid transporter
SA1140 0.00 5.59 Glycerol uptake facilitator
SA1960 0.00 3.85 PTS mannitol-speciﬁc IIBC component
SA0293 0.00 3.77 Hypothetical protein similar to formate transporter NirC
SA2156 0.00 3.72 Permease LctP homologue
SA0589 0.00 0.11 Hypothetical protein similar to ABC transporter ATP-binding protein
SA2303 0.00 0.21 Hypothetical protein similar to membrane-spanning protein
SA0208 0.00 0.13 Maltose/maltodextrin transport permease homologue
SA2302 0.00 0.31 Hypothetical protein similar to ABC transporter
SA0111 0.00 0.38 Lipoprotein
SA0848 0.00 0.35 Oligopeptide transport system ATP-binding OppF homologue
SA2167 0.00 2.69 PTS sucrose-speciﬁc component
SA0207 0.00 0.21 Hypothetical protein similar to maltose/maltodextrin-binding protein
SA0849 0.00 0.35 Hypothetical protein similar to binding protein OppA
Continued on following page
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metabolites occur, areas of signiﬁcant regulatory action can be
identiﬁed.
We ﬁrst determined the reporter metabolites from P values
obtained when the microarrays from all the different time
points were combined. One of the top-scoring reporter metab-
olites that were identiﬁed in this combined analysis was 5-amino-
levulinate, an intermediate in the synthesis of the electron
transporter heme. It is synthesized from glutamate-1-semial-
dehyde 2,1-aminomutase (encoded by hemL, SA1491) and fur-
ther metabolized by aminolevulinic acid dehydratase (encoded
by hemB, SA1492). The appearance of 5-aminolevulinate
TABLE 2—Continued
Function group and ORF (N315) P value
by t test
a
Fold
change
b Description
SA0432 0.00 2.52 PTS enzyme II, phosphoenolpyruvate dependent, trehalose speciﬁc
SA0209 0.00 0.20 Maltose/maltodextrin transport permease homologue
SA0206 0.00 0.20 Multiple sugar-binding transport protein
SA0640 0.00 2.01 Hypothetical protein similar to ABC transporter required for expression of
cytochrome bd
SA0172 0.00 2.19 Hypothetical protein similar to membrane protein LmrP
SA0186 0.00 0.38 Hypothetical protein similar to phosphotransferase enzyme II
SA0639 0.01 2.04 Hypothetical protein similar to ABC transporter required for expression of
cytochrome bd
SA0531 0.01 2.20 Proline/betaine transporter homologue
SA0417 0.01 2.15 Hypothetical protein similar to sodium-dependent transporter
SA0655 0.01 2.25 Fructose-speciﬁc permease
SA0374 0.01 0.39 Xanthine permease
SA2053 0.01 2.06 Glucose uptake protein homologue
SA2434 0.02 2.31 Fructose phosphotransferase system enzyme homologue
a Only ORFs with a P value by t test of 0.05 have been listed.
b Only ORFs with a fold change of 0.4 or 2.0 for the hemB mutant versus the parent strain have been listed.
TABLE 3. Results of Fisher’s exact test showing overrepresented groups of genes in the hemB mutant at different growth phases
Time when group is overrepresented and group name Group size
(total size  2,322)
Selection
group size
Selection
size P value
a
Pooled values of the whole time course 337
Metabolism of carbohydrates and related molecules 133 34 0.00
Membrane bioenergetics (electron transport chain and ATP synthase) 54 17 0.00
Transport/binding proteins and lipoproteins 256 53 0.00
Metabolism of nucleotides and nucleic acids 74 18 0.02
Phage-related functions 43 11 0.04
Adaptation to atypical conditions 44 11 0.04
Lag phase 279
Protein synthesis 85 25 0.00
Metabolism of nucleotides and nucleic acids 74 22 0.00
Metabolism of carbohydrates and related molecules 133 27 0.00
Adaptation to atypical conditions 44 12 0.00
Early logarithmic phase 171
Metabolism of carbohydrates and related molecules 133 27 0.00
Transport/binding proteins and lipoproteins 256 34 0.00
Adaptation to atypical conditions 44 7 0.04
Logarithmic phase 113
Metabolism of carbohydrates and related molecules 133 19 0.00
Metabolism of nucleotides and nucleic acids 74 10 0.00
Transport/binding proteins and lipoproteins 256 21 0.01
Early stationary growth phase 189
Membrane bioenergetics (electron transport chain and ATP synthase) 54 13 0.00
Metabolism of carbohydrates and related molecules 133 20 0.00
Transport/binding proteins and lipoproteins 256 31 0.01
Stationary growth phase 46
Membrane bioenergetics (electron transport chain and ATP synthase) 54 8 0.00
Protein synthesis 85 7 0.00
Metabolism of carbohydrates and related molecules 133 6 0.04
a Only groups that are overrepresented are listed.
7772 SEGGEWIß ET AL. J. BACTERIOL.might be explained by the following two possibilities: (i) the
up-regulation of hemL is an effect of the hemB knockout on
expression from a distal promoter and, thus, most likely from
the promoter of the hem operon (hemAXCDBL), or (ii) it is an
effect resulting from the erm promoter: only hemL (SA1491)
and hemB (SA1492) were found to be up-regulated whereas
none of the other hem genes that belong to the hem operon
(hemAXCD) showed a changed transcription proﬁle. This led
to the assumption that the change in transcription level is an
effect of the erm promoter, which is indeed located upstream of
hemL and upstream of the part of hemB spotted on the mi-
croarray. Therefore, it is assumed that the observed changes
are an effect of the erm promoter. In any case, the occurrence
of 5-aminolevulinate as a reporter metabolite provides evi-
dence that the employed pathway-driven analysis of microarray
data is able to uncover areas of regulatory action.
In the combined analysis of all time points, it was further
found that most of the signiﬁcant reporter metabolites (P 
0.05) cluster in three distinct metabolic regions: central carbon
metabolism, arginine and proline metabolism, and purine syn-
thesis (see Fig. S1 in the supplemental material). Below, we
will focus our discussion on these areas.
Arginine and proline metabolism. The mutation in hemB led
to an identiﬁcation of L-arginine, L-arginine (extracellular),
and L-ornithine (extracellular) as reporter metabolites, which
are all involved in the arginine-deiminase (AD) pathway. The
gene for the arginine/ornithine antiporter, arcD (SA2426),
showed a 16.29-fold-higher expression in the combined analy-
sis compared to the parent strain (Table 2). This reﬂects a
signiﬁcant difference between the hemB mutant and its paren-
tal strain. Similar changes were found for arcA (arginine de-
iminase, SA2428, 4.96-fold up-regulated) and arcB (ornithine
transcarbamoylase, SA2427, 4.24-fold up-regulated).
The hemB mutant may regulate the AD pathway through a
Crp/Fnr family transcriptional regulator. Fnr family regulators
have previously been linked to AD system regulation (16, 17,
31), and they have proven to be responsible for anaerobic gene
regulation in many gram-negative and some gram-positive bac-
teria (6, 12, 31). Particularly in Streptococcus suis, it has been
shown that the AD system is induced under microaerophilic
and anaerobic conditions (6). In accordance with the observa-
tions in S. suis, the S. aureus gene SA2424 product, a hypo-
thetical protein similar to the transcription regulator from the
Crp/Fnr family, was up-regulated in the hemB mutant (9.18-
fold, pooled values for all ﬁve time points) in comparison with
the parent strain, and it might play an important role in the
regulation of the AD pathway.
It was demonstrated that the AD system can be considered
a system that protects streptococci against acidic stress (2, 4),
a trait that would correlate with the ability of SCVs to persist
intracellularly (36). It may be assumed that the up-regulated
AD system allows S. aureus SCVs to counteract (through am-
monia production) the intracellular acidic environment. How-
ever, it is also conceivable that the hemB mutant uses this
pathway to produce ATP as was hypothesized in previous stud-
ies (7, 12).
Also from the arginine and proline metabolism, another set
of reporter metabolites was identiﬁed (L-4-hydroxyglutamate
semialdehyde, L-glutamate 5-semialdehyde, N2-succinyl-L-glu-
tamate, and N2-succinyl-L-glutamate 5-semialdehyde). The
genes whose products act on these metabolites are rocA
(SA2341) and rocD (SA0181), which are both down-regulated
FIG. 2. Clustered top-scoring reporter metabolites (P values  0.05) which occurred at more than one time point. Black boxes denote time
points when the respective metabolite that occurred was identiﬁed as signiﬁcant. CoA, coenzyme A; FAD, ﬂavin adenine dinucleotide; FADH2,
reduced ﬂavin adenine dinucleotide.
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strain. From the analysis of data collected from each phase of
bacterial growth (Fig. 2), signiﬁcant changes are evident only at
the second through the ﬁfth time point. These genes are in-
volved in arginine catabolism, where arginine is cleaved by
arginase to give ornithine, which is converted to glutamate
semialdehyde by ornithine aminotransferase (rocD gene prod-
uct). Finally, the conversion of glutamate semialdehyde to glu-
tamate is catalyzed by the rocA gene product. The roc pathway
is generally considered an aerobic pathway for the metabolism
of L-arginine that terminates in L-glutamate (17, 18). Poten-
tially, the down-regulation of rocA and rocD prevents a drain of
ornithine towards glutamate, which in turn would result in a
lower efﬁciency of the AD pathway to counteract acidic con-
ditions or provide ATP.
Central carbon metabolism. We identiﬁed a large number of
metabolites from central carbon metabolism as reporter me-
tabolites. More speciﬁcally, these metabolites belong to the
terminal part of glycolysis, glycerol metabolism, pyruvate me-
tabolism, and acetate metabolism and to the TCA cycle (Fig. 2
and 3).
The signiﬁcant changes in glycolysis on one hand were
caused by an up-regulation of an operon consisting of SA0727,
SA0728, SA0730, and SA0731 and on the other hand by a
signiﬁcant down-regulation of genes encoding two sets of
isoenzymes (SA1510 [homologous to SA0727] and SA2204
[homologous to SA0730]) (Fig. 3).
Genes encoding products responsible for the metabolism of
glycerol showed signiﬁcantly increased expression levels in the
hemB mutant (Fig. 3): glycerate kinase (SA2220, 3.25-fold),
glycerol diffusional facilitator (glpF, SA1140, 5.58-fold), and
aerobic glycerol-3-phosphate dehydrogenase (glpD, SA1142,
5.45-fold). glpD is known to be induced by glycerol and re-
pressed by glucose (14). Consistent with the model for expres-
sion of glycerol-3-phosphate dehydrogenase for Bacillus subti-
lis (22), the glycerol uptake operon antiterminator regulatory
protein (glpP, SA1139, 2.1-fold) was also up-regulated in the
hemB mutant compared to the parental strain. While a regu-
latory linkage in B. subtilis between antitermination by GlpP
and the phosphoenolpyruvate:sugar phosphotransferase sys-
tem (PTS) was described, phosphoenolpyruvate-protein phos-
phatase (ptsI, SA0935), one of the two major proteins of the
PTS, was found to be down-regulated in the hemB mutant
compared to its parental strain (0.59-fold). Of interest, a mu-
rine model revealed that an S. aureus ptsI mutant had a
10-fold-higher 50% lethal dose than its virulent wild-type strain
did (13).
Pyruvate as well as intra- and extracellular lactate also oc-
FIG. 3. Illustration of signiﬁcant transcriptional changes in the context of metabolic pathways of central carbon metabolism based on the
combined analysis of all time points. Metabolites in gray circles denote reporter metabolites (P values  0.05). Gene names are given in italics.
A gene’s down-regulation in the hemB mutant compared to the parental strain is indicated by a red box around the gene locus (based on the S.
aureus N315 sequence), and a gene’s up-regulation is indicated by a green box. Dark colors denote strong down- and up-regulation. PEP,
phosphoenolpyruvate; FAD, ﬂavin adenine dinucleotide; FADH2, reduced ﬂavin adenine dinucleotide.
7774 SEGGEWIß ET AL. J. BACTERIOL.curred as a reporter metabolite (Fig. 3). Here, signiﬁcant
changes occurred in the expression of both lactate dehydroge-
nases, which catalyze the reversible NAD-dependent intercon-
version of pyruvate to L-lactate, representing the ﬁnal step in
anaerobic glycolysis of lactic acid bacteria. The gene for the
anaerobic L-lactate dehydrogenase (lctE, SA0232) revealed a
dramatically increased expression (40.16-fold up-regulated in
the hemB mutant in comparison of pooled values), while the
aerobic L-lactate dehydrogenase (SA2395) was down-regu-
lated. This observation of an anaerobic metabolism occurring
in the hemB mutant is in line with earlier indications that
principally fermentative pathways are activated in the hemB
mutant (7). The massive up-regulation of the anaerobic L-
lactate dehydrogenase in the hemB mutant is obviously re-
quired for terminal oxidation of NADH. Simultaneously, the
gene encoding a lactate importer (lctP, SA0106) showed a
reduced expression level in the mutant, the reason for which
remains elusive.
In contrast to the parental strain, the hemB mutant shows a
lower level of acetate utilization (12). Accordingly, transcrip-
tional differences in acetate metabolism were found: with the
exception of the pyruvate oxidase (pox, SA2327), genes from
pathways leading to acetate were signiﬁcantly down-regulated
in the hemB mutant (Fig. 3). Pyruvate oxidase utilizes Pi to
produce acetyl-P (oxygen dependent), which in turn produces
ATP and acetate. The up-regulation of pyruvate oxidase can be
considered a clear beneﬁt for the energy-starved hemB mutant.
Despite the increased expression of genes belonging to
lower glycolysis and the pathway leading to lactate (Fig. 3), the
gene responsible for converting phosphoenolpyruvate to pyru-
vate (pyruvate kinase, pykA, SA1520) (bridging these two
aforementioned segments of increased expression) did not
change its expression level at all. Here, it is conceivable that
the signiﬁcantly increased expression of several PTSs (among
which is ptsG [SA2326], the PTS responsible for glucose up-
take) takes over the conversion of phosphoenolpyruvate to
pyruvate.
In the TCA cycle, several reporter metabolites occurred as a
result of a decreased expression of aconitate hydratase (citB,
SA1184, 0.34-fold), isocitrate dehydrogenase (citC, SA1517,
0.39-fold), and citrate synthase (citZ, SA1518, 0.42-fold). In
addition, intermediate compounds produced by the pyruvate
dehydrogenase and the oxoglutarate dehydrogenase complexes
were identiﬁed as reporter metabolites (Fig. 2 and 3). The
genes particularly contributing to this were pdhBCD (SA0944
to SA0946, 0.66-, 0.34-, and 0.50-fold changes, respectively),
odhAB (dihydrolipoamide succinyltransferase, SA1244, 0.20-
fold), and 2-oxoglutarate dehydrogenase E1 (SA1245, 0.26-
fold). Interestingly, these differences were signiﬁcant only at
the time points 2 through 5, representing early-exponential
through stationary growth (Fig. 2).
Purine biosynthesis. Our analysis identiﬁed several interme-
diates from the purine synthesis as reporter metabolites (see Fig.
S1 in the supplemental material; Fig. 2). The differently regulated
genes related to these metabolites were the genes of the pur
operon (comprising purCDEFHKLMNQ) (SA0918, SA0926,
SA1048, SA0922, SA0925, SA0917, SA0921, SA0923, SA0924,
and SA0920), folD (FolD bifunctional protein, SA0915), and
fhs (formyltetrahydrofolate synthetase, SA1553). All genes
showed a decreased expression proﬁle in the hemB mutant
compared to the parent strain (Table 2). The genes folD and
fhs strictly belong to the biosynthesis of folate coenzymes,
which are, however, required for purine synthesis. The analysis
of the different growth phases showed that the reported genes
are down-regulated only up to mid-log phase (time points 1 to
3, Fig. 2), while at the late exponential and stationary phases of
growth no difference between the hemB mutant and its paren-
tal strain was detected. Fisher’s exact test conﬁrmed these
ﬁndings for pooled values and lag through logarithmic phase as
given in Table 3.
In B. subtilis, a regulator protein, PurR (S. aureus homo-
logue SA0454), was found to repress purA (adenylosuccinate
synthase, S. aureus homologue SA0016), glyA (serine hydroxy-
methyl transferase, S. aureus homologue SA1915), folD, and
the complete pur operson (8). In Lactococcus lactis, an activa-
tor homologous to the B. subtilis purR repressor was identiﬁed
(11). We found that expression of staphylococcal purR was only
slightly elevated in the hemB mutant in contrast to its wild-type
progenitor strain (1.45-fold). The reason for the signiﬁcant
down-regulation of purine synthesis remains unknown.
Membrane bioenergetics. The phenotype of hemin-auxo-
troph SCVs is likely linked to disruption of electron transport
(25, 36). Consistent with this idea, all of the genes involved in
membrane bioenergetics were found to be overrepresented in
the combined analysis and in the stationary growth phase if
analyzed on its own. Affected genes were the NADH dehydro-
genase subunit (ndhF, SA0411, 5.0-fold), cytochrome d ubiquinol
oxidase subunit II homologue (SA0937, 2.13-fold), hypotheti-
cal protein similar to ferredoxin oxidoreductase beta subunit
(SA1132, 2.34-fold), cytochrome d ubiquinol oxidase subunit I
homologue (SA0937, 2.14-fold), hypothetical protein similar to
thioredoxin reductase (SA1311, 2.12-fold), and ferredoxin (fer,
SA1315, 2.31-fold).
Cell division and cell wall synthesis. S. aureus SCVs show
impaired cell separation and incomplete or multiple cell walls
(10). Genes involved in these processes were found to be
up-regulated in the hemB mutant, for example, pbpA (penicil-
lin-binding protein 1, SA1024, 2.4-fold), llm (lipophilic protein
affecting bacterial lysis rate and methicillin resistance, SA0702,
2.2-fold), pbp2 (penicillin-binding protein 2, SA1283, 2.4-fold),
and varS (two-component sensor histidine kinase, SA1701,
4.09-fold). VarS has been described as a sensor critical for the
control of penicillin-binding proteins (38). This protein may
play a major role in the alteration of expression of genes
involved in cell wall synthesis and cell division and, therefore,
may contribute to the reduced susceptibility of the hemB mu-
tant to antimicrobial agents.
CPs and adhesions. The role of the S. aureus capsule in the
pathogenesis of staphylococcal infections has been investigated
in several animal models of infection. Of interest, we found
that the genes for capsular polysaccharide (CP) synthesis,
capA, capB, capC, capD, capE, capF, and capG (SA0144 to
SA0150), were up-regulated in the hemB mutant compared to
the parent strain, especially at the lag phase and early loga-
rithmic phase. The group of genes for “adaptation to atypical
conditions,” which includes the genes encoding proteins re-
sponsible for capsular polysaccharide synthesis, were found to
be overrepresented at lag phase and early logarithmic phase
and also if values for all growth phases were pooled (Table 3).
These ﬁndings correlate with a previous study demonstrating
VOL. 188, 2006 S. AUREUS hemB MUTANT TRANSCRIPTIONAL PROFILE 7775growth-dependent expression of CPs (23). While CPs have
been shown to enhance virulence in animal models of staphy-
lococcal pathogenesis, antithetically they have been found to
reduce an early step in infection, bacterial adherence (32, 33).
However, our microarray experiments showed that when ex-
pression of genes for CPs was reduced, expression of genes for
adhesions was increased (e.g., ﬁbrinogen-binding protein A
[clfA, SA0742, 4.74-fold up-regulated in hemB mutant at early
logarithmic growth phase] and clumping factor B [clfB,
SA2423, 2.96-fold up-regulated in hemB mutant at logarithmic
growth phase]). Since adhesion to host cells represents the
precursor step to internalization for the bacteria within host
cells (5, 21), it may be assumed that up-regulation of genes
coding for adhesions may increase the hemB mutant’s ability to
invade and persist intracellularly.
In summary, while previously detected single genomic traits
of the S. aureus hemB mutant were conﬁrmed by this approach,
this full-genome microarray also offered a more complete
genomic analysis of the hemB mutant and provided insight into
the expression proﬁle. Profound differences were identiﬁed
especially in the purine biosynthesis as well as in the arginine
and proline metabolism. Of particular interest, a hypothetical
gene of the Crp/Fnr family (SA2424), being part of the AD
pathway, whose homologue in Streptococcus suis is assumed to
be involved in intracellular persistence, showed a signiﬁcantly
increased transcription in the hemB mutant. The hemB mutant
potentially uses the up-regulated AD pathway to produce ATP
or (through ammonia production) to counteract the acidic
environment that prevails intracellularly. The metabolic rear-
rangements may be responsible for the association of SCVs
with chronic and persistent infections. Furthermore, genes in-
volved in capsular polysaccharide and cell wall synthesis were
found to be signiﬁcantly up-regulated in the hemB mutant and
thus potentially responsible for the changed cell morphology of
SCVs and its consequences. Further work, however, is neces-
sary to decipher the regulatory program of the SCV pheno-
type.
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